The role of skn-1 in methylmercury-induced latent dopaminergic neurodegeneration

Neurochemical Research

Volumn 38, Issue 12, 2013, Pages 2650-2660

  Martinez Finley, Ebany J ^a,b   Caito, Samuel ^a,b   Slaughter, James C ^a   Aschner, Michael ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DAergic neurodegeneration; Early life exposure; Methylmercury; NRF2; skn 1

Indexed keywords

DOPAMINE; METHYLMERCURY; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; GENE; GENE FUNCTION; GENE SILENCING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIFESPAN; MASS SPECTROMETRY; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; SKN 1 GENE; STRAIN DIFFERENCE; STRESS; WILD TYPE;

CAENORHABDITIS ELEGANS;

ANIMALS; BASE SEQUENCE; BEHAVIOR, ANIMAL; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA PRIMERS; DNA-BINDING PROTEINS; DOPAMINE; MASS SPECTROMETRY; METHYLMERCURY COMPOUNDS; NERVOUS SYSTEM; TRANSCRIPTION FACTORS;

EID: 84890315354     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-013-1183-0     Document Type: Article

References (65)

1. Ni M et al (2010) Methylmercury induces acute oxidative stress, altering Nrf2 protein level in primary microglial cells. Toxicol Sci 116(2):590-603
2. An JH, Blackwell TK (2003) SKN-1 links C. elegans mesendodermal specification to a conserved oxidative stress response. Genes Dev 17(15):1882-1893
3. Vanduyn N et al (2010) SKN-1/Nrf2 inhibits dopamine neuron degeneration in a Caenorhabditis elegans model of methylmercury toxicity. Toxicol Sci 118(2):613-624
4. Kaidery NA et al (2013) Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxid Redox Signal 18(2):139-157
5. Ramsey CP et al (2007) Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 66(1):75-85
6. Lastres-Becker I et al (2012) Alpha-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Hum Mol Genet 21(14):3173-3192
7. Gorell JM et al (1999) Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 20(2-3):239-247
8. Gutteridge JM (1995) Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 41(12 Pt 2):1819-1828
9. Recchia A et al (2004) Alpha-synuclein and Parkinson's disease. FASEB J 18(6):617-626
10. Aschner M et al (2007) Involvement of glutamate and reactive oxygen species in methylmercury neurotoxicity. Braz J Med Biol Res 40(3):285-291
11. Zhang P et al (2009) In vitro protective effects of pyrroloquinoline quinone on methylmercury-induced neurotoxicity. Environ Toxicol Pharmacol 27(1):103-110
12. Chiueh CC et al (1994) In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann N Y Acad Sci 738:25-36
13. Dabbeni-Sala F et al (2001) Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J 15(1):164-170
14. De Iuliis A et al (2005) A proteomic approach in the study of an animal model of Parkinson's disease. Clin Chim Acta 357(2):202-209
15. Sherer TB et al (2003) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 179(1):9-16
16. Riederer P et al (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52(2):515-520
17. Sian J et al (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36(3):348-355
18. Sian J et al (1994) Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 36(3):356-361
19. Sofic E et al (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142(2):128-130
20. Bender A et al (2006) High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38(5):515-517
21. Cantuti-Castelvetri I et al (2005) Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiol Aging 26(10):1343-1355
22. Kraytsberg Y et al (2006) Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 38(5):518-520
23. Swerdlow RH et al (1996) Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40(4):663-671
24. Gorell JM et al (1999) Occupational metal exposures and the risk of Parkinson's disease. Neuroepidemiology 18(6):303-308
25. Gao Y et al (2008) Effects of methylmercury on postnatal neurobehavioral development in mice. Neurotoxicol Teratol 30(6):462-467
26. Lin FM, Malaiyandi M, Sierra CR (1975) Toxicity of methylmercury: effects on different ages of rats. Bull Environ Contam Toxicol 14(2):140-148
27. Maia CS (2010) Inhibitory avoidance acquisition in adult rats exposed to a combination of ethanol and methylmercury during central nervous system development. Behav Brain Res 211(2):191-197
28. Uchino M et al (1995) Neurologic features of chronic Minamata disease (organic mercury poisoning) certified at autopsy. Intern Med 34(8):744-747
29. Weiss B, Clarkson TW, Simon W (2002) Silent latency periods in methylmercury poisoning and in neurodegenerative disease. Environ Health Perspect 110(Suppl 5):851-854
30. Yoshida M et al (2008) Emergence of delayed methylmercury toxicity after perinatal exposure in metallothionein-null and wild-type C57BL mice. Environ Health Perspect 116(6):746-751
31. Yoshida M et al (2011) Neurobehavioral effects of combined prenatal exposure to low-level mercury vapor and methylmercury. J Toxicol Sci 36(1):73-80
32. Landrigan PJ et al (2005) Early environmental origins of neurodegenerative disease in later life. Environ Health Perspect 113(9):1230-1233
33. Helmcke KJ et al (2009) Characterization of the effects of methylmercury on Caenorhabditis elegans. Toxicol Appl Pharmacol 240(2):265-272
34. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25(4):402-408
35. Sawin ER, Ranganathan R, Horvitz HR (2000) C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron 26(3):619-631
36. Burbacher TM, Rodier PM, Weiss B (1990) Methylmercury developmental neurotoxicity: a comparison of effects in humans and animals. Neurotoxicol Teratol 12(3):191-202
37. Newland MC, Rasmussen EB (2000) Aging unmasks adverse effects of gestational exposure to methylmercury in rats. Neurotoxicol Teratol 22(6):819-828
38. Dare E et al (2003) Effects of prenatal exposure to methylmercury on dopamine-mediated locomotor activity and dopamine D2 receptor binding. Naunyn Schmiedebergs Arch Pharmacol 367(5):500-508
39. Reed MN, Newland MC (2009) Gestational methylmercury exposure selectively increases the sensitivity of operant behavior to cocaine. Behav Neurosci 123(2):408-417
40. Clarkson TW, Magos L (2006) The toxicology of mercury and its chemical compounds. Crit Rev Toxicol 36(8):609-662
41. Clarkson TW, Magos L, Myers GJ (2003) The toxicology of mercury - current exposures and clinical manifestations. N Engl J Med 349(18):1731-1737
42. Castoldi AF et al (2008) Neurodevelopmental toxicity of methylmercury: laboratory animal data and their contribution to human risk assessment. Regul Toxicol Pharmacol 51(2):215-229
43. Goulet S, Dore FY, Mirault ME (2003) Neurobehavioral changes in mice chronically exposed to methylmercury during fetal and early postnatal development. Neurotoxicol Teratol 25(3):335-347
44. Rodier PM (1995) Developing brain as a target of toxicity. Environ Health Perspect 103(Suppl 6):73-76
45. Rojo AI et al (2010) Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 58(5):588-598
46. Rushmore TH, Morton MR, Pickett CB (1991) The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 266(18):11632-11639
47. Enomoto A et al (2001) High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 59(1):169-177
48. Nguyen T et al (2005) Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J Biol Chem 280(37):32485-32492
49. Harman D (1956) Aging: a theory based on free radical and radiation chemistry. J Gerontol 11(3):298-300
50. Martinez-Finley EJ et al (2013) Manganese neurotoxicity and the role of reactive oxygen species. Free Radic Biol Med 62:65-75
51. Hagen TM (2003) Oxidative stress, redox imbalance, and the aging process. Antioxid Redox Signal 5(5):503-506
52. Li J, Holbrook NJ (2003) Common mechanisms for declines in oxidative stress tolerance and proliferation with aging. Free Radic Biol Med 35(3):292-299
53. Kregel KC, Zhang HJ (2007) An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Integr Comp Physiol 292(1):R18-R36
54. Kim HL, Seo YR (2012) Molecular and genomic approach for understanding the gene-environment interaction between Nrf2 deficiency and carcinogenic nickel-induced DNA damage. Oncol Rep 28(6):1959-1967
55. Yang B et al (2012) Deficiency in the nuclear factor E2-related factor 2 renders pancreatic beta-cells vulnerable to arsenic-induced cell damage. Toxicol Appl Pharmacol 264(3):315-323
56. Dhakshinamoorthy S, Jaiswal AK (2001) Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H: quinone oxidoreductase1 gene. Oncogene 20(29):3906-3917
57. Itoh K et al (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236(2):313-322
58. Suh JH et al (2004) Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci USA 101(10):3381-3386
59. Zimmer B et al (2011) Sensitivity of dopaminergic neuron differentiation from stem cells to chronic low-dose methylmercury exposure. Toxicol Sci 121(2):357-367
60. Itier JM et al (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12(18):2277-2291
61. Berman SB, Zigmond MJ, Hastings TG (1996) Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J Neurochem 67(2):593-600
62. Chen R et al (2007) Direct evidence that two cysteines in the dopamine transporter form a disulfide bond. Mol Cell Biochem 298(1-2):41-48
63. Johansson C et al (2007) Neurobehavioural and molecular changes induced by methylmercury exposure during development. Neurotox Res 11(3-4):241-260
64. Barker DJ (1992) The fetal origins of diseases of old age. Eur J Clin Nutr 46(Suppl 3):S3-S9
65. Barker DJ (1995) Fetal origins of coronary heart disease. BMJ 311(6998):171-174